

## **4P-Pharma appoints Sonia Escaich as Chief Operating Officer**

**Lille, France, 07 July 2020** – Today, 4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announced the appointment of Sonia Escaich, PhD, as Chief Operating Officer. In her role, Dr. Escaich will be central to coordinate scientific operations at 4P-Pharma as well as the strategic and business planning.

“Sonia has deep domain expertise from both drug development and business perspective, she will bring a wealth of experience to the team”, said Revital Rattenbach, Founder and President of 4P-Pharma. “Having founded 4P-Pharma with a patient focus, Sonia’s appointment broadens our senior expertise and will core to our goal of bringing 4P004, our Disease Modifying Osteoarthritis Drug, to the clinic by 2021. I have full confidence that she will help accelerate our scientific programs development and operational efficiencies that will take 4P-Pharma to the next level.”

“Sonia joins 4P-Pharma with a deep experience in both biotechnology and pharmaceutical companies. This is indeed a great time for 4P-Pharma and I look forward to her strong professional support to all of our R&D operations as well as funding opportunities”, added Dr. Patrice Denèfle, Chief Scientific Officer of 4P-Pharma.

Dr. Escaich brings over two decades of experience in pharmaceutical and biotechnology companies, including strategic and operational management, and R&D. Before joining 4P-Pharma, Dr. Escaich was consultant for drugs R&D biotechs. She has been, the Chief Operating Officer of Regulaxis, supervising the R&D operations of an osteoarthritis therapy toward the entry into clinic. She was also involved in the business strategy of the company. Prior to that, Dr. Escaich co-founded and headed for 8 years Mutabilis, a biotechnology company developing therapeutic molecules for the treatment of bacterial infections. She has also held leadership roles at Sandoz (Vienna, Austria), Sytemix (Palo Alto, USA), Sanofi Aventis, Fabpharma and Biosantech, ranging from director of research to executive director.

“4P-Pharma has built a strong pipeline of projects for bringing research results toward clinical applications. I am delighted to join 4P-Pharma dynamic team, and to participate to the development of its therapeutic innovations in fields with high medical needs”, said Dr. Escaich.

## About 4P-Pharma

4P-Pharma is a French biotechnology company specialized in the sourcing and the development of early stage therapeutic molecules addressing unmet medical needs for human and animal health. 4P-Pharma's strategy aims to detect the most promising early-stage projects from partners (i.e. academic institutions, small biotechs and TTOs) and perform in-house technological due-diligence applying stringent criteria. 4P-Pharma gather all the relevant actors from the clinic, drug development, finance and business fields to move technologies through developmental decision, building bridges to bring innovations to clinical phases and closer to patients' bedside. Since the foundation of 4P-Pharma in 2014, more than 250 molecules have been pre-evaluated, a technological due diligence has been carried out on 12 of them, and 2 have been selected to be developed until the clinical stage. One of these drug candidates, 4P004, is currently developed for the treatment of Osteoarthritis.

Website: [www.4p-pharma.com](http://www.4p-pharma.com)

LinkedIn: [www.linkedin.com/company/4p-pharma](https://www.linkedin.com/company/4p-pharma)

Twitter: @4P\_Pharma



### **4P-Pharma press contact**

**Roselina Lam**, Business Development & Licensing Manager

Phone: +33 7 49 16 02 27 – E-mail: [roselina@4p-pharma.com](mailto:roselina@4p-pharma.com)